Clinicians' preferences and attitudes towards the use of lithium in the maintenance treatment of bipolar disorders around the world: a survey from the ISBD Lithium task force.
Attitudes
Bipolar disorders
Lithium
Maintenance
Preferences
Survey
Treatment
Use
Journal
International journal of bipolar disorders
ISSN: 2194-7511
Titre abrégé: Int J Bipolar Disord
Pays: Germany
ID NLM: 101622983
Informations de publication
Date de publication:
27 May 2023
27 May 2023
Historique:
received:
16
11
2022
accepted:
08
05
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
Lithium has long been considered the gold-standard pharmacological treatment for the maintenance treatment of bipolar disorders (BD) which is supported by a wide body of evidence. Prior research has shown a steady decline in lithium prescriptions during the last two decades. We aim to identify potential factors explaining this decline across the world with an anonymous worldwide survey developed by the International Society for Bipolar Disorders (ISBD) Task Force "Role of Lithium in Bipolar Disorders" and distributed by diverse academic and professional international channels. A total of 886 responses were received of which 606 completed the entire questionnaire while 206 completed it partially. Respondents were from 43 different countries comprising all continents. Lithium was the most preferred treatment option for the maintenance of BD patients (59%). The most relevant clinical circumstances in which lithium was the preferred option were in patients with BD I (53%), a family history of response (18%), and a prior response during acute treatment (17%). In contrast, Lithium was not the preferred option in case of patients´ negative beliefs and/or attitudes towards lithium (13%), acute side-effects or tolerability problems (10%) and intoxication risk (8%). Clinicians were less likely to prefer lithium as a first option in BD maintenance phase when practising in developing economy countries [X2 (1, N = 430) = 9465, p = 0.002) ] and private sectors [X2 (1, N = 434) = 8191, p = 0.004)]. Clinicians' preferences and attitudes towards the use of lithium in the maintenance treatment of bipolar disorders appear to be affected by both the patients' beliefs and the professional contexts where clinicians provide their services. More research involving patients is needed for identifying their attitudes toward lithium and factors affecting its use, particularly in developing economies.
Sections du résumé
BACKGROUND
BACKGROUND
Lithium has long been considered the gold-standard pharmacological treatment for the maintenance treatment of bipolar disorders (BD) which is supported by a wide body of evidence. Prior research has shown a steady decline in lithium prescriptions during the last two decades. We aim to identify potential factors explaining this decline across the world with an anonymous worldwide survey developed by the International Society for Bipolar Disorders (ISBD) Task Force "Role of Lithium in Bipolar Disorders" and distributed by diverse academic and professional international channels.
RESULTS
RESULTS
A total of 886 responses were received of which 606 completed the entire questionnaire while 206 completed it partially. Respondents were from 43 different countries comprising all continents. Lithium was the most preferred treatment option for the maintenance of BD patients (59%). The most relevant clinical circumstances in which lithium was the preferred option were in patients with BD I (53%), a family history of response (18%), and a prior response during acute treatment (17%). In contrast, Lithium was not the preferred option in case of patients´ negative beliefs and/or attitudes towards lithium (13%), acute side-effects or tolerability problems (10%) and intoxication risk (8%). Clinicians were less likely to prefer lithium as a first option in BD maintenance phase when practising in developing economy countries [X2 (1, N = 430) = 9465, p = 0.002) ] and private sectors [X2 (1, N = 434) = 8191, p = 0.004)].
CONCLUSIONS
CONCLUSIONS
Clinicians' preferences and attitudes towards the use of lithium in the maintenance treatment of bipolar disorders appear to be affected by both the patients' beliefs and the professional contexts where clinicians provide their services. More research involving patients is needed for identifying their attitudes toward lithium and factors affecting its use, particularly in developing economies.
Identifiants
pubmed: 37243681
doi: 10.1186/s40345-023-00301-y
pii: 10.1186/s40345-023-00301-y
pmc: PMC10220344
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20Informations de copyright
© 2023. The Author(s).
Références
Andrade LH, Alonso J, Mneimneh Z, Wells JE, Al-Hamzawi A, Borges G, et al. Barriers to mental health treatment: results from the WHO World Mental Health surveys. Psychol Med. 2014;44(6):1303–17.
pubmed: 23931656
Bauer M. Lithium: What can we do to overcome the discrepancies between evidence,guideline recommendations and clinical practice? Eur Neuropsychopharmacol. 2022;60:1–3.
pubmed: 35397384
Bohlken J, Bauer M, Kostev K. Drug treatment for patients with bipolar disorders in psychiatric practices in Germany in 2009 and 2018. Psychiatry Res. 2020;289:112965.
pubmed: 32388174
Burgess SS, Geddes J, Hawton KK, Taylor MJ, Townsend E, Jamison K, et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev. 2001. https://doi.org/10.1002/14651858.CD003013 .
doi: 10.1002/14651858.CD003013
pubmed: 11687035
pmcid: 7005360
Carvalho AF, Solmi M, Husain MI, Berk M, Vieta E. The rebirth of lithium as the archetypal mood stabilizer. Bipolar Disord. 2021;23(2):211–2.
pubmed: 33188648
Chisholm D, Van Ommeren M, Ayuso-Mateos JL, Saxena S. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder. Br J Psychiatry. z2005;187(6):559–67.
pubmed: 16319409
Chou WYS, Oh A, Klein WMP. Addressing health-related misinformation on social media. JAMA. 2018;320(23):2417–8.
pubmed: 30428002
de Pérez X, Hidalgo-Mazzei D, Vieta E, González-Pinto A. Overview of lithium’s use: a nationwide survey. Int J Bipolar Disord. 2021;9(1):1–8.
Dell’Osso L, del Grande C, Gesi C, Carmassi C, Musetti L. A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts. Neuropsychiatr Dis Treat. 2016;12:1687.
pubmed: 27468233
pmcid: 4946830
Fountoulakis KN, Tohen M, Zarate CA. Lithium treatment of Bipolar disorder in adults: a systematic review of randomized trials and meta-analyses. Eur Neuropsychopharmacol. 2022;54:100.
pubmed: 34980362
pmcid: 8808297
Gomes FA, Brietzke E, Bauer M, Post RM. A call for improving lithium literacy among clinicians and patients. Int J Bipolar Disord. 2022;10(1):1–2.
Gomes-da-Costa S, Marx W, Corponi F, Anmella G, Murru A, Pons-Cabrera MT, et al. Lithium therapy and weight change in people with bipolar disorder: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2022;134:104266.
pubmed: 34265322
Grillault Laroche D, Etain B, Severus E, Scott J, Bellivier F. Socio-demographic and clinical predictors of outcome to long-term treatment with lithium in bipolar disorders: a systematic review of the contemporary literature and recommendations from the ISBD/IGSLI task force on treatment with lithium. Int J Bipolar Disord. 2020;8(1):1–13.
Grover S, Avasthi A, Chakravarty R, Dan A, Chakraborty K, Neogi R, et al. Prescription patterns in clinically stable patients with bipolar disorder: findings from the bipolar disorder course and outcome from India (BiD-CoIN) study. Asian J Psychiatr. 2021;57:102549.
pubmed: 33484992
Heeren O, Sánchez De Carmona M, Vásquez G, Córdoba R, Forero J, Madrid L, et al. Psychopharmacological treatment of bipolar disorder in Latin American. Revista de Psiquiatría y Salud Mental. 2011. https://doi.org/10.1016/j.rpsmen.2011.08.001 .
doi: 10.1016/j.rpsmen.2011.08.001
pubmed: 23446266
International Monetary Fund (IMF). World economic and financial surveys world economic outlook database—WEO groups and aggregates information. 2022.
Janet A, Butler DT. A survey of lithium monitoring and prescribing patterns. Int J Psychiatry Clin Pract. 2009;4(2):135–8.
Jauhar S, Young AH. Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy. Int J Bipolar Disord. 2019;7(1):10.
pubmed: 30915592
pmcid: 6435763
Jørgensen K, Rendtorff JD. Patient participation in mental health care–perspectives of healthcare professionals: an integrative review. Scand J Caring Sci. 2018;32(2):490–501.
pubmed: 28940229
Karanti A, Kardell M, Lundberg U, Landén M. Changes in mood stabilizer prescription patterns in bipolar disorder. J Affect Disord. 2016;195:50–6.
pubmed: 26859073
Kessing LV. Lithium as the drug of choice for maintenance treatment in bipolar disorder. Acta Psychiatr Scand. 2019;140(2):91–3.
pubmed: 31310342
Kessing LV. Lithium as the drug of choice for maintenance treatment in bipolar disorder. Acta Psychiatr Scand. 2019;140(2):91–3.
pubmed: 31310342
Khullar D. Social media and medical misinformation. JAMA. 2022;328(14):1393–4.
pubmed: 36149664
Lin SK, Yang SY, Park SC, Jang OJ, Zhu X, Xiang YT, et al. Prescription patterns for bipolar disorder in Asian Countries: findings from research on asian prescription pattern-bipolar disorder. Clin Psychopharmacol Neurosci. 2022;28(1):61–9.
Lindström L, Lindström E, Nilsson M, Höistad M. Maintenance therapy with second generation antipsychotics for bipolar disorder—a systematic review and meta-analysis. J Affect Disord. 2017;213:138–50.
pubmed: 28222360
Lyall LM, Penades N, Smith DJ. Changes in prescribing for bipolar disorder between 2009 and 2016: national-level data linkage study in Scotland. Br J Psychiatry. 2019;215(1):415–21.
pubmed: 30816839
pmcid: 6581537
Malhi GS, Adams D, Berk M. Is lithium in a class of its own? A Brief Profile of Its Clinical Use. 2009. https://doi.org/10.3109/00048670903279937 .
doi: 10.3109/00048670903279937
Malhi GS, Bell E, Boyce P, Hazell P, Murray G, Bassett D, et al. Make lithium great again! Bipolar Disord. 2020;22(4):325–7.
pubmed: 32521095
Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord. 2017;217:266–80.
pubmed: 28437764
Mandal S, Mamidipalli S, Mukherjee B, Hara S. Perspectives, attitude, and practice of lithium prescription among psychiatrists in India. Indian J Psychiatry. 2019;61(5):451.
pubmed: 31579157
pmcid: 6767820
Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(1):351–9.
pubmed: 26360999
Muhorakeye O, Biracyaza E. Exploring barriers to mental health services utilization at kabutare district hospital of Rwanda: perspectives from patients. Front Psychol. 2021;12:638377.
pubmed: 33828506
pmcid: 8019821
Murru A, Manchia M, Hajek T, Nielsen RE, Rybakowski JK, Sani G, et al. Lithium’s antiviral effects: a potential drug for CoViD-19 disease? Int J Bipolar Disord. 2020;8(1):19.
Nederlof M, Heerdink ER, Egberts ACG, Wilting I, Stoker LJ, Hoekstra R, et al.Monitoring of patients treated with lithium for bipolar disorder: an international survey. Int J Bipolar Disord. 2018;6(1):1–9.
Nestsiarovich A, Gaudiot CES, Baldessarini RJ, Vieta E, Zhu Y, Tohen M. Preventing new episodes of bipolar disorder in adults: systematic review and meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2022;54:75–89.
pubmed: 34489127
Nielsen R, Kessing L, Nolen W, Licht R. Lithium and renal impairment: a review on a still hot topic. Pharmacopsychiatry. 2018;51(05):200–5.
pubmed: 29346806
Nikolova VL, Pattanaseri K, Hidalgo-Mazzei D, Taylor D, Young AH. Is lithium monitoring NICE? Lithium monit UK secondary care sett. 2018. https://doi.org/10.1177/0269881118760663 .
doi: 10.1177/0269881118760663
Nolen WA, Licht RW, Young AH, Malhi GS, Tohen M, Vieta E, et al. What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI task force on treatment with lithium. Bipolar Disord. 2019;21(5):394–409.
pubmed: 31112628
pmcid: 6688930
Pacciardi B, Palagini L, Mainardi C, Cotugno B, Cargioli C, Perugi G, et al. Attitude toward prescription and clinical monitoring of lithium salts in a sample of Italian psychiatrists: preliminary data. Off J Ital Soc Psychopathol. 2017;23:172–9.
Paton C, Barnes TRE, Shingleton-Smith A, McAllister-Williams HR, Kirkbride J, Jones PB, et al. Lithium in bipolar and other affective disorders: prescribing practice in the UK. J Psychopharmacol. 2010;24(12):1739–46.
pubmed: 20488832
Rathod S, Pinninti N, Irfan M, Gorczynski P, Rathod P, Gega L, et al. Mental health service provision in low- and middle-income countries. Health Serv Insights. 2017. https://doi.org/10.1177/1178632917694350 .
doi: 10.1177/1178632917694350
pubmed: 28469456
pmcid: 5398308
Rhee TG, Olfson M, Nierenberg AA, Wilkinson ST. 20-years Trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry. 2020;177(8):706.
pubmed: 32312111
pmcid: 7577523
Rybakowski JK. Lithium. Eur Neuropsychopharmacol. 2022;57:86–7.
pubmed: 35189567
Samalin L, Genty JB, Boyer L, Lopez-Castroman J, Abbar M, Llorca PM. Shared decision-making: a systematic review focusing on mood disorders. Curr Psychiatry Rep. 2018;20:1–1.
Samalin L, Honciuc M, Boyer L, de Chazeron I, Blanc O, Abbar M, et al. Efficacy of shared decision-making on treatment adherence of patients with bipolar disorder: a cluster randomized trial (ShareD-BD). BMC Psychiatry. 2018;18(1):1.
Schoretsanitis G, de Filippis R, Brady BM, Homan P, Suppes T, Kane JM. Prevalence of impaired kidney function in patients with long-term lithium treatment: a systematic review and meta-analysis. Bipolar Disord. 2022;24(3):264–74.
pubmed: 34783413
Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014;47(2):43–52.
pubmed: 24549862
Shulman KI, Almeida OP, Herrmann N, Schaffer A, Strejilevich SA, Paternoster C, et al. Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: an ISBD task force report. Bipolar Disord. 2019;21(2):117–23.
pubmed: 30375703
Sköld M, Rolstad S, Joas E, Kardell M, Pålsson E, Goodwin GM, et al. Regional lithium prescription rates and recurrence in bipolar disorder. Int J Bipolar Disord. 2021;9(1):1–9.
Smith KA, Cipriani A. Lithium and suicide in mood disorders: updated meta-review of the scientific literature. Bipolar Disord. 2017;19(7):575–86.
pubmed: 28895269
Strejilevich SA, Urtueta-Baamonde M, Teitelbaum J, Martino DJ, Marengo E, Igoa A, et al. Clinical concepts associated with lithium underutilization in the treatment of bipolar disorder. Vertex. 2011;22:3–20.
pubmed: 21898968
Williams F, Boren SA. The role of the electronic medical record (EMR) in care delivery development in developing countries: a systematic review. Inf Prim Care. 2008;16(2):139–45.
Won E, Kim YK. An oldie but goodie: lithium in the treatment of bipolar disorder through neuroprotective and neurotrophic mechanisms. Int J Mol Sci. 2017;18(12):2679.
pubmed: 29232923
pmcid: 5751281
World Health Organization (WHO). mhGAP intervention guide for mental, neurological and substance use disorders in nonspecialized health settings: mental health gap action programme (mhGAP). 2016.
Young AH, Hammond JM. Lithium in mood disorders: increasing evidence base, declining use?. Br J Psychiatry. 2007;191(6):474–6.
pubmed: 18055949